PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBotulinum toxin type a
Botox cosmetic, Nuceiva(botulinum toxin type a)
Nuceiva (botulinum toxin type a) is a protein pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
integumentary system physiological phenomenaD055827
Trade Name
FDA
EMA
Botox, Daxxify, Dysport, Xeomin (discontinued: Botox)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abobotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
DysportabobotulinumtoxinAIpsenN-125274 RX2009-04-29
2 products
Incobotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
XeominincobotulinumtoxinAMerzN-125360 RX2010-07-30
3 products
Daxibotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
DaxxifydaxibotulinumtoxinA-lanmRevance TherapeuticsN-761127 RX2022-09-07
2 products
Onabotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
Botox CosmeticonabotulinumtoxinAAbbVieN-103000 RX1991-12-09
2 products
Botox onabotulinumtoxinAAbbVieN-103000 RX1991-12-09
2 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
babybigBiologic Licensing Application2024-12-05
botoxBiologic Licensing Application2023-11-18
botox cosmeticBiologic Licensing Application2024-10-18
botox facial serumC2002632024-10-28
botox serumC2002632024-11-03
botox stock solutionC2002632024-11-03
botulinum toxin solution anti-aging serumC2002632024-10-21
daxxifyBiologic Licensing Application2024-01-24
dysportBiologic Licensing Application2024-10-24
protoxinunapproved drug other2016-11-10
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
genetic skin diseases—D012873—
dystonia—D004421—
fissure in ano—D005401K60.2
strabismus—D013285H50.2
blepharospasm—D001764G24.5
muscle rigidity—D009127—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1461 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FaciesD019066—————2—2
SeizuresD012640—G40.4———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43——2——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0—1———1
Essential tremorD020329EFO_0003108G25.0—1———1
TremorD014202—R25.1—1———1
Abdominal herniaD046449—K46—1———1
Ventral herniaD006555EFO_1001866K43—1———1
HerniaD006547—K40-K46—1———1
Internal herniaD000082122———1———1
NeuralgiaD009437EFO_0009430——1———1
Interstitial cystitisD018856EFO_1000869N30.1—1———1
SyndromeD013577———1———1
Show 2 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Muscle spasticityD009128——1———12
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral palsyD002547—G80————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBotulinum toxin type a
INN—
Description
Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
Classification
Neurotoxin
Drug classfluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4297862
ChEBI ID—
PubChem CID—
DrugBankDB00083
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Botox – Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Botox – Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Daxxify – Revance Therapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Botulinum toxin type a
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,370 documents
View more details
Safety
Black-box Warning
Black-box warning for: Botox, Botox cosmetic, Daxxify, Dysport, Xeomin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,438 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use